Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1994 Jun;49(6):531–532. doi: 10.1136/thx.49.6.531

Diffuse panbronchiolitis and cystic fibrosis: East meets West.

N Høiby
PMCID: PMC474936  PMID: 8016786

Full text

PDF
531

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akai S., Okayama H., Shimura S., Tanno Y., Sasaki H., Takishima T. Delta F508 mutation of cystic fibrosis gene is not found in chronic bronchitis with severe obstruction in Japan. Am Rev Respir Dis. 1992 Sep;146(3):781–783. doi: 10.1164/ajrccm/146.3.781. [DOI] [PubMed] [Google Scholar]
  2. Anwar H., Dasgupta M. K., Costerton J. W. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother. 1990 Nov;34(11):2043–2046. doi: 10.1128/aac.34.11.2043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berger M. Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good? Clin Rev Allergy. 1991 Spring-Summer;9(1-2):119–142. doi: 10.1007/978-1-4612-0475-6_8. [DOI] [PubMed] [Google Scholar]
  4. Collins F. S. Cystic fibrosis: molecular biology and therapeutic implications. Science. 1992 May 8;256(5058):774–779. doi: 10.1126/science.1375392. [DOI] [PubMed] [Google Scholar]
  5. Fujita J., Nakamura H., Yamagishi Y., Yamaji Y., Shiotani T., Irino S. Elevation of plasma truncated elastase alpha 1-proteinase inhibitor complexes in patients with inflammatory lung diseases. Chest. 1992 Jul;102(1):129–134. doi: 10.1378/chest.102.1.129. [DOI] [PubMed] [Google Scholar]
  6. Goldstein W., Döring G. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis. 1986 Jul;134(1):49–56. doi: 10.1164/arrd.1986.134.1.49. [DOI] [PubMed] [Google Scholar]
  7. Homma H., Yamanaka A., Tanimoto S., Tamura M., Chijimatsu Y., Kira S., Izumi T. Diffuse panbronchiolitis. A disease of the transitional zone of the lung. Chest. 1983 Jan;83(1):63–69. doi: 10.1378/chest.83.1.63. [DOI] [PubMed] [Google Scholar]
  8. Høiby N., Koch C. Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management. Thorax. 1990 Nov;45(11):881–884. doi: 10.1136/thx.45.11.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ichikawa Y., Koga H., Tanaka M., Nakamura M., Tokunaga N., Kaji M. Neutrophilia in bronchoalveolar lavage fluid of diffuse panbronchiolitis. Chest. 1990 Oct;98(4):917–923. doi: 10.1378/chest.98.4.917. [DOI] [PubMed] [Google Scholar]
  10. Ichikawa Y., Ninomiya H., Koga H., Tanaka M., Kinoshita M., Tokunaga N., Yano T., Oizumi K. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis. 1992 Jul;146(1):196–203. doi: 10.1164/ajrccm/146.1.196. [DOI] [PubMed] [Google Scholar]
  11. Iino Y., Toriyama M., Kudo K., Natori Y., Yuo A. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann Otol Rhinol Laryngol Suppl. 1992 Oct;157:16–20. doi: 10.1177/0003489492101s1005. [DOI] [PubMed] [Google Scholar]
  12. Koch C., Høiby N. Pathogenesis of cystic fibrosis. Lancet. 1993 Apr 24;341(8852):1065–1069. doi: 10.1016/0140-6736(93)92422-p. [DOI] [PubMed] [Google Scholar]
  13. Koyama H., Nishimura K., Mio T., Ikeda A., Sugiura N., Izumi T. Bronchial responsiveness and acute bronchodilator response in chronic obstructive pulmonary disease and diffuse panbronchiolitis. Thorax. 1994 Jun;49(6):540–544. doi: 10.1136/thx.49.6.540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kronborg G., Hansen M. B., Svenson M., Fomsgaard A., Høiby N., Bendtzen K. Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. Pediatr Pulmonol. 1993 May;15(5):292–297. doi: 10.1002/ppul.1950150506. [DOI] [PubMed] [Google Scholar]
  15. Littlewood J. M., Smye S. W., Cunliffe H. Aerosol antibiotic treatment in cystic fibrosis. Arch Dis Child. 1993 Jun;68(6):788–792. doi: 10.1136/adc.68.6.788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McElvaney N. G., Hubbard R. C., Birrer P., Chernick M. S., Caplan D. B., Frank M. M., Crystal R. G. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet. 1991 Feb 16;337(8738):392–394. doi: 10.1016/0140-6736(91)91167-s. [DOI] [PubMed] [Google Scholar]
  17. McElvaney N. G., Nakamura H., Birrer P., Hébert C. A., Wong W. L., Alphonso M., Baker J. B., Catalano M. A., Crystal R. G. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest. 1992 Oct;90(4):1296–1301. doi: 10.1172/JCI115994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nagai H., Shishido H., Yoneda R., Yamaguchi E., Tamura A., Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration. 1991;58(3-4):145–149. doi: 10.1159/000195915. [DOI] [PubMed] [Google Scholar]
  19. Nakamura H., Yoshimura K., McElvaney N. G., Crystal R. G. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest. 1992 May;89(5):1478–1484. doi: 10.1172/JCI115738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Noda Y., Yasuoka S., Inoue I., Tani K., Fujisawa K., Ogura T. Analysis of IgA antibody to Pseudomonas aeruginosa in sera and sputa of patients with chronic airway diseases. Intern Med. 1992 May;31(5):575–582. doi: 10.2169/internalmedicine.31.575. [DOI] [PubMed] [Google Scholar]
  21. Sakata K., Yajima H., Tanaka K., Sakamoto Y., Yamamoto K., Yoshida A., Dohi Y. Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro. Am Rev Respir Dis. 1993 Oct;148(4 Pt 1):1061–1065. doi: 10.1164/ajrccm/148.4_Pt_1.1061. [DOI] [PubMed] [Google Scholar]
  22. Suter S. The imbalance between granulocyte neutral proteases and antiproteases in bronchial secretions from patients with cystic fibrosis. Antibiot Chemother (1971) 1989;42:158–168. doi: 10.1159/000417616. [DOI] [PubMed] [Google Scholar]
  23. Tamaoki J., Chiyotani A., Tagaya E., Sakai N., Konno K. Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax. 1994 Jun;49(6):545–548. doi: 10.1136/thx.49.6.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Tanimoto H. A review of the recent progress in treatment of patients with diffuse panbronchiolitis associated with Pseudomonas aeruginosa infection in Japan. Antibiot Chemother (1971) 1991;44:94–98. doi: 10.1159/000420303. [DOI] [PubMed] [Google Scholar]
  25. Wisnieski J. J., Todd E. W., Fuller R. K., Jones P. K., Dearborn D. G., Boat T. F., Naff G. B. Immune complexes and complement abnormalities in patients with cystic fibrosis. Increased mortality associated with circulating immune complexes and decreased function of the alternative complement pathway. Am Rev Respir Dis. 1985 Oct;132(4):770–776. doi: 10.1164/arrd.1985.132.4.770. [DOI] [PubMed] [Google Scholar]
  26. Yasuoka S., Fujisawa K., Ueta Y., Nii Y., Inoue I., Tani K., Ohgushi F., Ogura T. Cell profile and elastase activity in diffuse panbronchiolitis investigated by bronchoalveolar and bronchial lavage. Intern Med. 1992 May;31(5):599–605. doi: 10.2169/internalmedicine.31.599. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES